Risankizumab治疗难治性克罗恩病的真实世界有效性:RISANCROHN研究
基于ENEIDA登记处的多中心观察性研究纳入857例以难治性为主的成人克罗恩病患者,评估Risankizumab的短期及末次随访有效性。第8-12周无激素临床缓解率为56%,末次随访(平均7.4个月)为61%;既往生物制剂暴露≤2种者缓解率更高(p<0.001)。治疗相关不良事件发生率8%,无严重不良事件。
要点
- Risankizumab在难治性克罗恩病中第8-12周无激素临床缓解率达56%
- 末次随访(平均7.4个月)无激素临床缓解率为61%
- 既往生物制剂暴露≤2种者缓解率显著高于>2种者(p<0.001)
核心结论
- Risankizumab在难治性克罗恩病真实世界队列中实现有临床意义的无激素临床缓解,早期和末次随访均有效。
- 疗效主要受累积生物制剂暴露影响,安全性良好。
研究设计与样本
- 多中心观察性研究,纳入ENEIDA登记处857例以难治性为主的成人克罗恩病患者。
- 主要终点为第8-12周及末次随访的无激素临床缓解(Harvey-Bradshaw指数≤4且未用全身皮质类固醇)。
- 采用多因素logistic回归分析末次随访缓解相关因素。
主要发现
- 第8-12周无激素临床缓解率为56%,末次随访(平均7.4个月)为61%。
- 既往暴露≤2种生物制剂者缓解率在兩個时间点均高于>2种者(p<0.001)。
- 既往乌司奴单抗暴露在未校正分析中与较低缓解率相关,但末次随访时非独立相关。
- 治疗相关不良事件发生率8%,无严重不良事件。
关键数值与推荐
- 无激素临床缓解定义为Harvey-Bradshaw指数≤4且未用全身皮质类固醇。
- 第8-12周缓解率56%,末次随访缓解率61%(平均随访7.4个月)。
- 既往生物制剂暴露≤2种 vs >2种者缓解率差异p<0.001。
- 治疗相关不良事件8%,无严重不良事件。
临床怎么用
- Risankizumab可用于难治性克罗恩病,早期和中期均能实现无激素临床缓解。
- 既往生物制剂暴露种类较少的患者可能获益更大。
- 治疗相关不良事件发生率较低,安全性良好。
局限性
- 观察性研究设计,可能存在混杂偏倚。
- 随访时间较短(平均7.4个月),缺乏长期疗效数据。
- 未报告内镜结局等客观指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Risankizumab, a selective interleukin-23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate-to-severe Crohn's disease, but real-world data in highly refractory populations are limited. We evaluated the short-term effectiveness and outcomes at last follow-up of risankizumab and the impact of prior advanced therapy exposure. METHODS: This multicentre observational study included adult patients with predominantly refractory Crohn's disease treated with risankizumab and registered in the ENEIDA registry. Steroid-free clinical remission, defined as a Harvey-Bradshaw Index ≤ 4 without systemic corticosteroids, was assessed at weeks 8-12 and at the last available follow-up visit. Multivariable logistic regression was used to identify factors associated with remission at last follow-up. RESULTS: A total of 857 patients with predominantly refractory Crohn's disease were included. Steroid-free clinical remission was achieved in 56% of patients at weeks 8-12 and in 61% at last follow-up (mean follow-up: 7.4 months). Remission rates were higher in patients previously exposed to ≤ 2 biologic therapies than in those exposed to > 2 biologic therapies at both time points (p < 0.001). Prior ustekinumab exposure was associated with lower remission rates in unadjusted analyses but was not independently associated with remission at last follow-up. Treatment-related adverse events occurred in 8% of patients, with no serious adverse events. CONCLUSIONS: In this large real-world cohort of patients with refractory Crohn's disease, risankizumab achieved clinically meaningful steroid-free clinical remission, both at early assessment and at last follow-up, with effectiveness primarily influenced by cumulative biologic exposure and demonstrating a favourable safety profile.
引用
- Barreiro-de Acosta M, Zabana Y, Nieto-García L, et al. Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry. Aliment Pharmacol Ther. 2026. PMID: 42267647. doi:10.1111/apt.70783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。